Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda F Baker

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Atherosclerosis|May 2, 2025
Corrigendum to "Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA" [Atherosclerosis (2025) 403 119114]Eliot A Brinton, Robert H Eckel, Daniel Gaudet, et al.
Atherosclerosis|March 11, 2025
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNAEliot A Brinton, Robert H Eckel, Daniel Gaudet, et al.
Nucleic Acid Therapeutics|December 21, 2018
Integrated Assessment of the Clinical Performance of GalNAc<sub>3</sub>-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer ExperienceStanley T Crooke, Brenda F Baker, Shuting Xia, et al.
Diabetes Care|February 14, 2018
Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B<sub>Rx</sub> Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 DiabetesAndres Digenio, Nguyen C Pham, Lynnetta M Watts, et al.
Journal of the American Heart Association|July 12, 2014
Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteersRobert Noveck, Erik S G Stroes, JoAnn D Flaim, et al.
Nucleic Acid Therapeutics|November 30, 2017
The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in HumansStanley T Crooke, Brenda F Baker, Nguyen C Pham, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alphaK Lea Sewell, Richard S Geary, Brenda F Baker, et al.
Journal of Medicinal Chemistry|June 25, 2005
Positional effect of chemical modifications on short interference RNA activity in mammalian cellsThazha P Prakash, Charles R Allerson, Prasad Dande, et al.
Circulation|October 13, 2006
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein BJohn J P Kastelein, Mark K Wedel, Brenda F Baker, et al.
European Heart Journal|May 20, 2011
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemiaFatima Akdim, Diane L Tribble, JoAnn D Flaim, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Atherosclerosis|May 2, 2025
Corrigendum to "Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA" [Atherosclerosis (2025) 403 119114]Eliot A Brinton, Robert H Eckel, Daniel Gaudet, et al.
Atherosclerosis|March 11, 2025
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNAEliot A Brinton, Robert H Eckel, Daniel Gaudet, et al.
Nucleic Acid Therapeutics|December 21, 2018
Integrated Assessment of the Clinical Performance of GalNAc<sub>3</sub>-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer ExperienceStanley T Crooke, Brenda F Baker, Shuting Xia, et al.
Diabetes Care|February 14, 2018
Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B<sub>Rx</sub> Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 DiabetesAndres Digenio, Nguyen C Pham, Lynnetta M Watts, et al.
Journal of the American Heart Association|July 12, 2014
Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteersRobert Noveck, Erik S G Stroes, JoAnn D Flaim, et al.
Nucleic Acid Therapeutics|November 30, 2017
The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in HumansStanley T Crooke, Brenda F Baker, Nguyen C Pham, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alphaK Lea Sewell, Richard S Geary, Brenda F Baker, et al.
Journal of Medicinal Chemistry|June 25, 2005
Positional effect of chemical modifications on short interference RNA activity in mammalian cellsThazha P Prakash, Charles R Allerson, Prasad Dande, et al.
Circulation|October 13, 2006
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein BJohn J P Kastelein, Mark K Wedel, Brenda F Baker, et al.
European Heart Journal|May 20, 2011
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemiaFatima Akdim, Diane L Tribble, JoAnn D Flaim, et al.
Pageof 6